Related Experiment Videos
ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation
BMJ (Clinical Research Ed.)
|January 6, 1996
Insights
Long-term warfarin or aspirin significantly lowers thromboembolic risk in atrial fibrillation patients. Routine identification, risk assessment, and review are crucial for effective management.
Area of Science:
- Cardiology
- Internal Medicine
- Pharmacology
Background:
- Atrial fibrillation poses a significant risk of thromboembolic events.
- Antithrombotic therapy is a cornerstone in managing this risk.
Purpose of the Study:
- To emphasize the importance of identifying and assessing thromboembolic risk in atrial fibrillation patients.
- To highlight the role of antithrombotic prophylaxis in reducing this risk.
Main Methods:
- Review of existing literature and clinical guidelines on atrial fibrillation management.
- Clinical risk stratification methods for thromboembolic events.
Main Results:
- Long-term use of warfarin or aspirin effectively reduces thromboembolic risk.
- Clinical assessment is sufficient for initial risk stratification.
- Echocardiography can further refine risk assessment.
Conclusions:
- Antithrombotic prophylaxis is essential for patients with atrial fibrillation.
- Systematic identification, risk assessment, and regular review of these patients should be standard practice.
- Clinical evaluation is a practical approach to risk stratification, complemented by echocardiography for refinement.
Abstract:
Antithrombotic prophylaxis with long term warfarin or aspirin reduces thromboembolic risk in atrial fibrillation. Identification, risk assessment, and regular review of all patients with atrial fibrillation should be routine in general and hospital practice. Risk stratification is easily performed on clinical grounds--echocardiography may refine it.